There are currently no approved treatments, or preventive vaccines
for COVID-19, the highly contagious, sometimes deadly respiratory
illness caused by the new coronavirus. Researchers are studying
existing treatments and working on experimental ones, but most
current patients receive only supportive care such as breathing
assistance.
Hydroxychloroquine, a malaria drug, is among the medications that
are being tested, as a potential treatment for patients with the
disease. Earlier this week, the American Society of Health-System
Pharmacists (ASHP), which maintains a list of drug shortages, said
hydroxychloroquine was in shortage.
"Chloroquine has demonstrated toxicity in certain patients," Dinesh
Dua, chairman of the Pharmaceuticals Export Promotion Council of
India, told Reuters. "You have to tread with caution because there
is no comprehensive data to prove it works."
The group said India faced no shortages of the drug but they warned
companies were facing acute shortages of staff to run operations.
[to top of second column] |
Late on Tuesday, India ordered a 21-day lockdown of its 1.3 billion people to
try to protect the world's second most populous country from the fast-spreading
coronavirus.
"It is impossible to maintain operations due to lockdown, because employees
don't want to come," Dua said.
India has already banned export of all ventilators and sanitizers and personal
protection equipment such as masks and clothing to contain the outbreak that has
so far infected more than 550 people and claimed close to a dozen lives in the
country.
The ban comes after India, the world's largest supplier of generic drugs, this
month restricted the export of 26 pharmaceutical ingredients and the medicines
made from them, including Paracetamol, a common pain reliever also sold as
acetaminophen, as the coronavirus outbreak plays havoc with supply chains. Some
of those restrictions have since been relaxed.
For an interactive graphic tracking global spread of coronavirus: open https://tmsnrt.rs/3aIRuz7
in an external browser.
(Reporting by Neha Dasgupta; Editing by Euan Rocha and Edwina Gibbs)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |